{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:52:57Z","timestamp":1761562377814,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T00:00:00Z","timestamp":1526688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Scripps Clinic Medical Group","award":["Research","Education Award"],"award-info":[{"award-number":["Research","Education Award"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s10620-018-5108-2","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T06:44:54Z","timestamp":1526712294000},"page":"2445-2450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?"],"prefix":"10.1007","volume":"63","author":[{"given":"Sajiv","family":"Chandradas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamed","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connor","family":"Wayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren","family":"Reidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Waalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4221-4579","authenticated-orcid":false,"given":"Gauree G.","family":"Konijeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,19]]},"reference":[{"key":"5108_CR1","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/ajg.2013.4","volume":"108","author":"CM Surawicz","year":"2013","unstructured":"Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478\u2013498. quiz 99.","journal-title":"Am J Gastroenterol"},{"key":"5108_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40121-016-0117-y","volume":"5","author":"LE Bloomfield","year":"2016","unstructured":"Bloomfield LE, Riley TV. Epidemiology and risk factors for community-associated Clostridium difficile infection: a narrative review. Infect Dis Ther. 2016;5:231\u2013251.","journal-title":"Infect Dis Ther"},{"key":"5108_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cgh.2006.12.028","volume":"5","author":"M Issa","year":"2007","unstructured":"Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345\u2013351.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5108_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/cid\/cit280","volume":"57","author":"J Bishara","year":"2013","unstructured":"Bishara J, Farah R, Mograbi J, et al. Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis. 2013;57:489\u2013493.","journal-title":"Clin Infect Dis"},{"key":"5108_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/apt.13832","volume":"45","author":"R Mulki","year":"2017","unstructured":"Mulki R, Baumann AJ, Alnabelsi T, et al. Body mass index greater than 35 is associated with severe Clostridium difficile infection. Aliment Pharmacol Ther. 2017;45:75\u201381.","journal-title":"Aliment Pharmacol Ther"},{"key":"5108_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.orcp.2013.12.007","volume":"9","author":"E Punni","year":"2015","unstructured":"Punni E, Pula JL, Asslo F, Baddoura W, DeBari VA. Is obesity a risk factor for Clostridium difficile infection? Obes Res Clin Pract. 2015;9:50\u201354.","journal-title":"Obes Res Clin Pract"},{"key":"5108_CR7","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1111\/j.1572-0241.2007.01439.x","volume":"102","author":"C Sousa Guerreiro","year":"2007","unstructured":"Sousa Guerreiro C, Cravo M, Costa AR, et al. A comprehensive approach to evaluate nutritional status in Crohn\u2019s patients in the era of biologic therapy: a case-control study. Am J Gastroenterol. 2007;102:2551\u20132556.","journal-title":"Am J Gastroenterol"},{"key":"5108_CR8","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1007\/s10620-017-4745-1","volume":"62","author":"L Haas","year":"2017","unstructured":"Haas L, Chevalier R, Major BT, Enders F, Kumar S, Tung J. Biologic agents are associated with excessive weight gain in children with inflammatory bowel disease. Dig Dis Sci. 2017;62:3110\u20133116. \n                    https:\/\/doi.org\/10.1007\/s10620-017-4745-1\n                    \n                  .","journal-title":"Dig Dis Sci"},{"key":"5108_CR9","doi-asserted-by":"publisher","first-page":"e0186575","DOI":"10.1371\/journal.pone.0186575","volume":"12","author":"F Scaldaferri","year":"2017","unstructured":"Scaldaferri F, D\u2019Ambrosio D, Holleran G, et al. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with infliximab. PLoS ONE. 2017;12:e0186575.","journal-title":"PLoS ONE"},{"key":"5108_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1097\/MIB.0000000000001179","volume":"23","author":"L Guerbau","year":"2017","unstructured":"Guerbau L, Gerard R, Duveau N, et al. Patients with crohn\u2019s disease with high body mass index present more frequent and rapid loss of response to infliximab. Inflamm Bowel Dis. 2017;23:1853\u20131859.","journal-title":"Inflamm Bowel Dis"},{"key":"5108_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/MIB.0000000000001057","volume":"23","author":"G Kistangari","year":"2017","unstructured":"Kistangari G, Lopez R, Shen B. Frequency and risk factors of Clostridium difficile infection in hospitalized patients with pouchitis: a population-based study. Inflamm Bowel Dis. 2017;23:661\u2013671.","journal-title":"Inflamm Bowel Dis"},{"key":"5108_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrgastro.2012.152","volume":"9","author":"C Manichanh","year":"2012","unstructured":"Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599\u2013608.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5108_CR13","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1086\/657319","volume":"202","author":"AR Manges","year":"2010","unstructured":"Manges AR, Labbe A, Loo VG, et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis. 2010;202:1877\u20131884.","journal-title":"J Infect Dis"},{"key":"5108_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1099\/0022-1317-51-5-448","volume":"51","author":"MJ Hopkins","year":"2002","unstructured":"Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol. 2002;51:448\u2013454.","journal-title":"J Med Microbiol"},{"key":"5108_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ajg.2009.727","volume":"105","author":"A Kornbluth","year":"2010","unstructured":"Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501\u2013523. quiz 24.","journal-title":"Am J Gastroenterol"},{"key":"5108_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cgh.2016.10.024","volume":"15","author":"S Khanna","year":"2017","unstructured":"Khanna S, Shin A, Kelly CP. Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the clinical practice updates committee of the AGA institute. Clin Gastroenterol Hepatol. 2017;15:166\u2013174.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5108_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-2036.2009.04037.x","volume":"30","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253\u2013264.","journal-title":"Aliment Pharmacol Ther"},{"key":"5108_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/ajg.2016.187","volume":"111","author":"R Razik","year":"2016","unstructured":"Razik R, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol. 2016;111:1141\u20131146.","journal-title":"Am J Gastroenterol"},{"key":"5108_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1586\/17474124.2013.832501","volume":"7","author":"SM Vindigni","year":"2013","unstructured":"Vindigni SM, Broussard EK, Surawicz CM. Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol. 2013;7:615\u2013628.","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5108-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5108-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T12:49:27Z","timestamp":1558270167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5108-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,19]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["5108"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5108-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2018,5,19]]},"assertion":[{"value":"30 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Gauree Gupta Konijeti: Previously received honoraria from Abbvie, Janssen, Pfizer, and Takeda. The other authors report no relevant conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}